Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

What Factors Are Associated with Diagnostic Follow-Up after Abnormal Mammograms? Findings from a U.S. National Survey

K. Robin Yabroff, Nancy Breen, Sally W. Vernon, Helen I. Meissner, Andrew N. Freedman and Rachel Ballard-Barbash
K. Robin Yabroff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy Breen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sally W. Vernon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helen I. Meissner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew N. Freedman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel Ballard-Barbash
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2004
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The purpose of this study was to identify factors associated with diagnostic follow-up after an abnormal mammogram in a national sample of women in the U.S. The sample was selected from the year 2000 National Health Interview Survey and included 1901 women aged 30 and above who reported ever having an abnormal mammogram. The outcome measure was receipt of at least some diagnostic follow-up after an abnormal mammogram. Bivariate and multivariate logistic regression analyses were used to explore the associations between sociodemographic characteristics, general health and health behaviors, cancer risk and risk perceptions, and health care utilization characteristics and follow-up. Approximately 9% of women who reported ever having abnormal mammograms reported not completing any additional diagnostic follow-up. Controlling for all other factors, women with less than a high school education were less likely to report follow-up after an abnormal mammogram than were women who had at least completed college (odds ratio = 0.56; 95% confidence interval: 0.32, 0.98). Younger women and women in poorer health were also less likely to report follow-up. Women who perceived a high versus low level of cancer in their family were more likely to report follow-up (odds ratio = 1.65; 95% confidence interval: 1.04, 2.62), controlling for all other factors. In a national sample of women with abnormal mammograms, a substantial number did not complete any diagnostic follow-up, potentially reducing the effectiveness of mammography screening programs in the U.S. Additional research on subsequent screening behaviors for women with incomplete follow-up and in-depth exploration of the roles of patient-provider interactions and health care system factors related to the index abnormal mammogram is warranted.

  • follow-up studies
  • mammography
  • breast neoplasms
  • mass screening

Introduction

Regular mammography use is associated with earlier stage of breast cancer at diagnosis and improved breast cancer survival in clinical trials (1, 2). Although the magnitude of the mortality benefit associated with screening has been debated (3), most evidence-based guidelines continue to recommend regular screening (4, 5). Mammography use has increased dramatically in the past two decades in the United States (6, 7), yet in some populations, particularly racial minorities, and the poor or medically underserved, the percentage of women with advanced disease at diagnosis remains high (8–11). A potential explanation is that follow-up after an abnormal mammogram is delayed or incomplete, and thus, the benefits of screening are not being realized.

Prior studies have reported that between 32% and 98% of women with abnormal mammograms receive at least some follow-up (12–26). This wide range may be due, in part, to study differences in the severity of the underlying abnormal mammogram, the time period for follow-up assessment, and the definition of follow-up services (27). Patient characteristics associated with incomplete follow-up of abnormal screening tests include being poor or uneducated (13, 20), a racial or ethnic minority (13, 22, 28), and under- or uninsured (13). Women with delayed or incomplete follow-up of abnormal screening tests have also been reported to have high levels of cancer-specific anxiety (12) or fatalistic beliefs and misconceptions about cancer (29). Such attitudes and beliefs are more common among minority, low income, or uninsured women (29, 30). However, most studies of follow-up after abnormal mammograms have been conducted in populations within health insurance systems (24), health care facilities (15, 17), programs with income-eligibility requirements (22, 25), or racial groups (12), and as a result, little work has been done to disentangle the effects of race, socioeconomic status, health beliefs and behaviors, and health care access factors on follow-up of abnormal mammograms.

We used a national sample of women in the U.S. who had ever had an abnormal mammogram to explore the roles of race, socioeconomic status, health behaviors, health care access factors, and cancer risk perceptions on completion of diagnostic follow-up.

Methods

Sample

The sample for this study was selected from the year 2000 National Health Interview Survey (NHIS), an annual multistage survey conducted in the civilian population of the U.S. The sampling strategy is designed to yield nationally representative estimates of health and health behavior. The NHIS is an in-person, household survey and all data are self-report. Both Black and Hispanic populations are oversampled. The Cancer Control Module contains questions about cancer screening and follow-up, and had an overall response rate of 72.1%. More information on survey design and content is available from http://www.cdc.gov/nchs/nhis.htm.

Women aged 30 and above were asked if they had ever had a mammogram, and those that had were asked the age at the first mammogram, number of mammograms within the past 6 years, and a series of questions related to the most recent mammogram. Women were then asked “Have you ever had a mammogram where the results were NOT normal?” The study sample included all women aged 30 and above who reported ever having had an abnormal mammogram and who responded to a follow-up question about the type of diagnostic follow-up (N = 1901; weighted N = 11.5 million women).

Measures

We incorporated elements of several theoretical models of health care utilization in this analysis. First, we used a modified version of the Andersen and Aday model of realized access to health care (31–33) to guide selection of variables potentially associated with follow-up of abnormal mammograms. This model depicts the interaction of patients and providers within the health care system and their social environment. An important aspect of the model is the outcome of realized access to care or the use of needed medical services. Patient level components of the model that may either facilitate or impede the receipt of follow-up care include sociodemographic characteristics, general health and health behaviors, and health care utilization characteristics. Additionally, because behavioral models of health care utilization, such as the Health Belief Model (34), include perceived susceptibility or severity of disease as components of health behaviors, we also included variables related to cancer risk and risk perceptions.

The outcome measure in this study was receipt of at least some diagnostic follow-up after an abnormal mammogram. Respondents were asked to list all additional tests or procedures they received, which were coded into the following categories: additional imaging; clinical examination or surgical consult; biopsy or fine-needle aspiration; breast or lump removed; or no follow-up. We categorized follow-up as a binary variable—completed at least some follow-up or did not complete any follow-up (yes, no).

Sociodemographic characteristics were measured by age at the time of the survey (<50, 50–64, 65+), race (White, non-Hispanic, Black, non-Hispanic, and Hispanic/Other), immigrant status (born in the U.S. versus other), marital status (married or living as married versus other), educational attainment (less than high school graduate, high school graduate, at least some college), and income level in relation to the poverty level (0–149%, 150–299%, 300–449%, and 450%+). Residence was also characterized by geographic region (Northeast, Midwest, South, or West), and community size [Metropolitan Statistical Area (MSA), non-MSA].

General health and health behaviors were measured by health status (excellent/very good, good, fair/poor/missing), problems with activities of daily living (yes, no), problems with instrumental activities of daily living (yes, no), body mass index (<24.9, 25–29.9, 30+), chronic anxiety or depression (yes, no), and cigarette smoking status (current, former, or never smoker). Compliance with regular mammography was calculated for the subset of women aged 55–79, and was defined as having the most recent mammogram within the past 2 years and at least three mammograms in the past 6 years (yes, no) (35). This age range was chosen because it includes a sufficient number of years for a woman to have received three mammograms on a biannual schedule starting at age 50, the age where most guidelines have consistently recommended mammography screening initiation (4, 5).

Breast cancer risk was measured by the number of first-degree relatives with breast cancer under the age of 50 (0, 1+) and the Gail breast cancer risk score (36, 37). This score is based on current age, age at first live birth, age at menarche, number of first-degree relatives with breast cancer, and number of breast biopsies, and was used to calculate 5-year risk of breast cancer (<1.67%, 1.67%+). Respondents reported their perceived risk of getting cancer in the future as low, medium, or high and the amount of cancer they perceived in their family as low, medium, or high. Both variables were coded in these response categories (low, medium, high).

Health care utilization characteristics were measured by type of health insurance coverage [private/military, public only (i.e., Medicaid, Medicare without additional Medigap policies), no health insurance], whether or not the health insurance required approval for specialty care (yes, no), and whether the woman had a usual source of sick care (yes, no), or preventive care (yes, no). Primary care (yes, no) or specialist visits (yes, no) in the past year were also used to measure heath care utilization. Barriers to care included delayed or incomplete medical care due to cost or worry about cost (yes, no) or delayed or incomplete medical care for any other reason (yes, no).

Analyses

Descriptive statistics were calculated for the study sample of women who ever had an abnormal mammogram. Bivariate and multivariate logistic regression analyses were used to explore whether follow-up after an abnormal mammogram was associated with sociodemographic characteristics, general health and health behaviors, health care access factors, and cancer risk and risk perceptions.

Multivariate models were fitted in a stage-wise fashion within each component of the theoretical framework. Covariates with a dose-response association with the outcome variable or an association with the outcome variable in bivariate analyses at P < 0.20 were retained for separate component-specific intermediate multivariate models (i.e., sociodemographic characteristics, general health and health behaviors, health care utilization characteristics, and cancer risk perceptions). Covariates with associations with the outcome variable of P < 0.20 in intermediate models were retained for the final multivariate model. Potential interactions were assessed with stratified analyses and interaction terms for race/ethnicity and immigrant status, geographic region and MSA, and type of health insurance and requirement for specialty referral. The statistical software SUDAAN (38) was used to incorporate the complex NHIS sample design and weights in descriptive statistics and logistic regressions.

Compliance with regular mammography use and recent specialist visit were not included in bivariate or multivariate analyses because additional mammographic imaging or consultation with a breast surgeon are also follow-up procedures for an abnormal mammogram. Similarly, the Gail risk score was reported descriptively only because biopsy is a component of the Gail risk score and is a procedure used in the follow-up of abnormal mammograms.

Results

Sample Characteristics

Approximately 40% of women in the study sample were between the ages of 50 and 64, with about 34% aged less than 50 and the remaining 26% aged 65 or above (Table 1). The vast majority of women who reported having an abnormal mammogram were White, non-Hispanic, born in the U.S., with at least a high school education. Most women in the sample rated their health as excellent or very good, had few health limitations as measured by activities of daily living or instrumental activities of daily living, and had never smoked. Among the subset of women aged 55–79 (N = 763), 85.2% were compliant with regular, on-going mammography screening.

View this table:
  • View inline
  • View popup
Table 1.

Distribution of characteristics of women who reported ever having an abnormal mammogram (N = 1901)

Approximately 14% of the sample had one or more first-degree relatives with breast cancer, and less than one-quarter had elevated 5-year breast cancer risk as measured by the Gail model, estimated their risk of getting cancer in the future as high, or perceived the amount of cancer in their family as high. More than 90% of the sample had access to care as measured by health insurance coverage, a usual source of preventive care, sick care, or having seen a primary care physician within the past 12 months. Less than 15% delayed care in the past 12 months because of cost or other reasons.

In response to the type of follow-up completed, 8.6% [95% confidence interval: 7.2%, 10.0%] of the sample reported they received no follow-up. The weighted estimate is approximately 1 million women nationally who ever had an abnormal mammogram and received no follow-up. Most women who completed at least some follow-up had more than one type of test including additional mammographic or ultrasound imaging (55%), removal of a lump (32%), biopsy or fine needle aspiration (30%), or a clinical examination or surgical consultation (13%). These percentages add to more than 100% because the process of diagnostic follow-up may include a series of tests or procedures. Of the group of women who completed at least some follow-up, 15% reported that the additional results indicated breast cancer (data not shown).

Bivariate and Multivariate Logistic Regression Results

Sociodemographic Characteristics. Black, non-Hispanic, and Hispanic women were less likely to report follow-up than White, non-Hispanic women in bivariate analyses (Table 2), but when the other demographic characteristics were included in the intermediate multivariate model, this association was no longer statistically significant. Low socioeconomic status, measured by either educational attainment or poverty level income threshold was associated with reported follow-up in bivariate analyses with a clear dose response pattern. Educational attainment was included in the final, multivariate model (Table 3). Women with less than a high school education were less likely to report follow-up compared with women with at least a college degree, controlling for all other factors. Women living in the South and Northeast were less likely to report follow-up compared with women living in the Midwest, although this association was of borderline significance for women in the Northeast. Finally, younger women (<50) were less likely to complete at least some follow-up than women aged 65 and above in multivariate analyses.

View this table:
  • View inline
  • View popup
Table 2.

Bivariate associations between characteristics of women with abnormal mammograms and completion of at least some follow-up

View this table:
  • View inline
  • View popup
Table 3.

Multivariate associations between characteristics of women with abnormal mammograms and completion of at least some diagnostic follow-up

General Health and Health Behaviors. Women who reported their health as being good or fair/poor compared with very good/excellent were less likely to complete at least some diagnostic follow-up in bivariate and multivariate analyses.

Breast Cancer Risk Factors and Cancer Risk Perceptions. In general, as risk or perceived risk of cancer increased, so did likelihood of completing at least some diagnostic follow-up. Women who indicated the amount of cancer in their family was high were more likely to complete at least some follow-up compared with women with a low amount of cancer in the family.

Health Care Utilization Characteristics. Women with no health insurance or only public health insurance were less likely to complete at least some follow-up in bivariate analyses, but this estimate was no longer significant after controlling for other variables in the final model. Women who did not get needed medical care or who delayed care because of worry about cost were less likely to complete at least some follow-up in bivariate analyses, although the estimate was not significant in multivariate analyses.

None of the interactions tested was significantly associated with completion of at least some follow-up in intermediate multivariate models and were therefore not included in the final model.

Discussion

This is one of the first studies in the U.S. to use nationally representative data to explore the association between receipt of follow-up care after abnormal mammograms and sociodemographic factors, general health and health behaviors, cancer risk and risk perceptions, and health care utilization. Approximately 9% of our sample, almost 1 million women, did not complete any diagnostic follow-up after abnormal mammograms. Even though lack of follow-up for a specific abnormal mammogram may not be associated with a diagnosis of advanced breast cancer, women without cancer who do not complete any diagnostic follow-up may also fail to return to breast cancer screening, may delay seeking care should they have breast cancer symptoms in the future, or may fail to initiate other types of cancer screening. Women who have breast cancer at the time of an abnormal mammogram, but do not comply with diagnostic follow-up may have more advanced disease at diagnosis. Studies have shown that diagnostic delays as short as 3 months following symptom identification are associated with poorer breast cancer survival (39). Thus, delayed or incomplete follow-up after an abnormal screening test is an important component of the breast cancer screening process and its role in future screening behaviors and stage of disease at diagnosis is an important area for additional research. Mammography registries with linkages to tumor registries, such as the Breast Cancer Surveillance Consortium (40), or other state-based or health plan-based programs (41–43) might be useful data sources for this research because they contain women-level longitudinal data on mammography screening, abnormal mammograms, subsequent screening, and breast cancer diagnoses.

Another strength of the study was the breadth of detail in the NHIS that allowed us to use a theoretical framework to explore factors associated with follow-up after abnormal mammograms. Our findings support the usefulness of this framework in that variables representing major components of the model, including sociodemographic factors, general health and health behaviors, and cancer risk and risk perceptions were associated with follow-up after abnormal mammograms. More specifically, women who were younger, less educated, in poorer health, and who perceived low levels of cancer in their families were less likely to complete any follow-up after an abnormal mammogram. We also identified geographic variation in completion of at least some follow-up. Our findings help to identify additional variables that might more fully elaborate model components in future research studies of factors associated with receipt of follow-up care after abnormal screening tests.

One of our objectives for this study was to provide insight into the relative importance of race/ethnicity, other sociodemographic characteristics, and health care utilization characteristics on completion of at least some follow-up after abnormal mammograms. Although minority women were less likely to report follow-up after abnormal mammograms in bivariate analyses, once educational attainment, age, and geographic region were included in an intermediate multivariate model of socioeconomic characteristics, this effect diminished. Educational attainment, on the other hand, was associated with reported follow-up, controlling for all other factors. We did not have measures of health literacy or numeracy, communication about abnormal findings, or comprehension of follow-up recommendation, factors likely to be reflected in an association between low educational attainment and incomplete follow-up. Future in-depth studies of follow-up care after abnormal screening tests might include these measures in addition to race/ethnicity and measures of sociodemographic status. Inclusion of measures of health literacy and comprehension of abnormal findings will also be important elements for future enhancements of theoretical models of health care access and utilization.

In this study, we found that women who perceived the level of cancer in their family to be high were more likely to complete at least some diagnostic follow-up than were similar women who perceived low levels of cancer in their family. Perceived level of cancer in the family is a subjective measure of general cancer risk, however, and does not necessarily reflect objective breast cancer risk, such as the Gail model risk score (36). Others have reported that fatalism, cancer-specific anxiety, fear of diagnostic tests, or worry about cancer are associated with delayed or incomplete follow-up of abnormal screening tests (12, 29), although associations with objective measures of cancer risk are less clear. The inter-relationship between subjective and objective measures of breast cancer risk in relation to follow-up behaviors is likely to be complex and is an important area for additional research, particularly within a theoretical framework.

Our sample included only women who understood and reported they had an abnormal mammogram. Several studies have reported that physicians do not always inform patients about abnormal screening results (44) or recommend complete diagnostic evaluation (45–49). Two findings are potentially of interest in relation to physician communication about, and recommendation for follow-up care—younger women and women in poorer health were less likely to report any follow-up care. Physicians may be less inclined to strongly recommend diagnostic follow-up for women younger than 50, in whom breast cancer incidence is low, or women of poorer health status, who may be perceived as having less benefit from treatment. Inclusion of physician factors such as training, screening practice patterns, or beliefs about screening efficacy, and characteristics of the physician-patient interaction and follow-up recommendation are particularly relevant in future, in-depth research.

We also identified geographic variation in completion of at least some follow-up. Compared with women living in the Midwest, women living in the South and Northeast were less likely to complete at least some follow-up after an abnormal mammogram. Geographic variation in receipt of follow-up care may reflect patterns of unmeasured population characteristics; differences in state-based insurance, screening legislation, or health care programs; physician practice patterns or practice styles, medical care infrastructure, or other area-level factors. Such variation might be explored further with multi-level models with woman-level characteristics, physician characteristics, and state-based or area level medical and socioeconomic characteristics.

Our finding that approximately 9% of women did not complete at least some follow-up after an abnormal mammogram is not directly comparable to prior estimates of receipt of follow-up care after abnormal mammograms (12, 20–22, 24–26, 28). This estimate is based on self-report, includes abnormal mammograms of all levels of severity, is not linked to a single abnormal mammogram, and is not based on a specific time period (e.g., 30 days, 60 days). The majority of prior studies identified women through medical records, grouped abnormal mammograms by type of follow-up recommendation, and used a specific time period to assess receipt of follow-up care.

Finally, our findings may be broadly applicable to improving understanding of factors affecting diagnostic follow-up of other cancer screening tests. Effective screening tests are also available for early detection of cervical and colorectal cancer (50–53), and receipt of follow-up after abnormal results with these screening tests has also been reported to be sub-optimal (17, 45, 47, 48, 54–81); with the vast majority of studies reporting that fewer than 75% of patients completed follow-up (27). As with studies of receipt of follow-up care after abnormal mammograms, variation in these estimates may be due in part to study differences in the severity of the underlying abnormal finding, the time period for follow-up assessment, and the criteria used to define completeness of follow-up services (27). Similar to studies of receipt of follow-up care after abnormal mammograms, patient factors associated with incomplete follow-up of abnormal cervical cancer screening tests also include low socioeconomic status, lack of health insurance, and belonging to a racial or ethnic minority group (54, 69, 82, 83). Additionally, women who have problems coping with abnormal Pap tests, fear painful invasive procedures, or who worry about cancer are less likely to complete follow-up (62, 67, 82, 84). Less work has been done to assess patient-level factors associated with follow-up care after abnormal colorectal cancer screening tests (27), although it is likely that similar patient factors may also be important for the receipt of follow-up care after abnormal colorectal cancer screening results.

The majority of patient-targeted interventions developed to improve follow-up care after abnormal screening tests are effective; strategies include telephone counseling, educational pamphlets, telephone and mailed reminders, and lay health workers (85). To date, the vast majority of these patient-targeted interventions have been developed to improve adherence to receipt of follow-up care after abnormal Pap tests (27). Adaptation of these successful strategies to improve follow-up care after abnormal mammograms will be an important area for future research.

Despite the strengths of having a large nationally representative sample with detail on patient characteristics, health, and health behaviors to assess factors associated with the receipt of follow-up care, this study has several limitations related to the lack of detailed information about the abnormal mammogram and use of self-report data. No data were available on recommended follow-up for the abnormal mammogram, and as a result, follow-up procedures cannot be linked to their underlying recommendations. Additionally, information was not available about the timing of the abnormal mammogram in relation to the survey or about whether it was a screening mammogram or the result of a specific breast symptom. It is also possible that some women may have had an abnormal finding with a 6-month follow-up recommendation just before participation in the survey and not had the opportunity to complete diagnostic follow-up.

The questions we used to measure different components of the theoretical framework were not specific to the abnormal mammogram and in some cases were based on health care use in the past 12 months, whereas abnormal mammograms could have occurred at any time in the past. Additionally, health care access and utilization characteristics may change over time, potentially limiting the identification of associations between variables measuring these constructs and the receipt of follow-up care. For example, compared with individuals with continuous health insurance coverage, individuals with intermittent coverage have been shown to have lower preventive service utilization, although not as low as individuals who are continuously uninsured (86). Grouping individuals with intermittent insurance coverage with either individuals continuously insured or individuals continuously uninsured would diminish observed differences between these groups. Other variables, such as educational attainment, are less likely to change over time in an adult population, minimizing limitations in measurement.

These data in the NHIS are self-report and women may have difficulties remembering the specific procedure or a complicated series of procedures that constitute diagnostic follow-up (87). We used completion of at least some follow-up as the outcome variable, thus minimizing any problems with recall of specific procedures. Although other studies found that patients overreport screening compared with the medical record (88–91), potentially due, in part, to the desire to appear compliant with recognized health behaviors (87), it is unlikely that patients would overidentify themselves as having an abnormal mammogram for social desirability reasons. Finally, although the NHIS oversampled African Americans and Hispanics, there were too few women with abnormal mammograms in other minority groups, such as Asian Americans, to estimate their receipt of follow-up care separately. Such associations might be explored in greater detail with the 2001 California Health Interview Survey, a state-based survey with a similar cancer control module conducted in the nation's most racially, ethnically, and linguistically diverse population (92). A major goal of federal co-sponsorship of this survey was to enable investigators to better estimate cancer risk factors and cancer screening behaviors in racial and ethnic subgroups, such as Asian Americans and Native Americans.

In conclusion, the results of our study indicate that approximately 1 million women in the U.S. reported having had an abnormal mammogram without any diagnostic follow-up, potentially reducing the effectiveness of mass screening programs. Patient-level sociodemographic factors, general health and health behaviors, and cancer risk perceptions were associated with completion of at least some follow-up in multivariate analysis. Our findings may be broadly applicable to receipt of follow-up care after other abnormal cancer screening tests. Exploration of the association between incomplete follow-up and future screening behaviors, as well as the roles of health literacy, provider communication and recommendations, risk perceptions, and health care utilization factors are important areas for additional in-depth research. Ideally, such research should be designed and conducted within theoretical models of health care utilization that reflect health care delivery in the U.S.

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted January 27, 2004.
    • Received September 30, 2003.
    • Revision received December 3, 2003.

References

  1. ↵
    Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S. Report of the International Workshop on Screening for Breast Cancer. J Natl Cancer Inst 1993;85:1644–56.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Shapiro S, Venet W, Strax P, Venet L, Roeser R. Ten-to-fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst 1982;69:349-355.
  3. ↵
    Gotzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet 2000;355:129-34.
    OpenUrlCrossRefPubMed
  4. ↵
    Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:347-60.
    OpenUrlCrossRefPubMed
  5. ↵
    Leitch AM, Dodd GD, Costanza M, et al. American Cancer Society guidelines for the early detection of breast cancer: update 1997. CA Cancer J Clin 1997;47:150-3.
    OpenUrlPubMed
  6. ↵
    Breen N, Wagener DK, Brown ML, Davis WW, Ballard-Barbash R. Progress in cancer screening over a decade: results of cancer screening from the 1987, 1992, and 1998 national health interview surveys. J Natl Cancer Inst 2001;93:1704-13.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Blackman DK, Bennett EM, Miller DS. Trends in self-reported use of mammograms (1989–1997) and Papanicolaou tests (1991–1997)—Behavioral Risk Factor Surveillance System. Mor Mortal Wkly Rep CDC Surveill Summ 1999;48:1-22.
  8. ↵
    Bentley JR, Delfino RJ, Taylor TH, Howe S, Anton-Culver H. Differences in breast cancer stage at diagnosis between non-Hispanic white and Hispanic populations, San Diego County 1988–1993. Breast Cancer Res Treat 1998;50:1-9.
    OpenUrlCrossRefPubMed
  9. ↵
    Catalano RA, Satariano WA. Unemployment and the likelihood of detecting early-stage breast cancer. Am J Public Health 1998;88:586-9.
    OpenUrlPubMed
  10. ↵
    Ries LAG, Kosary CL, Hankey BF, Edwards BK. SEER Cancer Statistic Review, 1973–1996. Bethesda, MD: National Cancer Institute; 1999.
  11. ↵
    Merkin SS, Stevenson L, Powe N. Geographic socioeconomic status, race, and advanced-stage breast cancer in New York City. Am J Public Health 2002;92:64-70.
    OpenUrlPubMed
  12. ↵
    Kerner JF, Yedidia M, Padgett D, et al. Realizing the promise of breast cancer screening: clinical follow-up after abnormal screening in Black women. Prev Med 2003;37:92-101.
    OpenUrlCrossRefPubMed
  13. ↵
    Strzelczyk JJ, Dignan MB. Disparities in adherence to recommended follow-up on screening mammography: interaction of sociodemographic factors. Ethn Dis 2002;12:77-86.
    OpenUrlPubMed
  14. ↵
    Robertson CL, Kopans DB. Communication problems after mammographic screening. Radiology 1989;172:443-4.
    OpenUrlPubMed
  15. ↵
    Helvie MA, Pennes DR, Rebner M, Adler DD. Mammographic follow-up of low-suspicion lesions: compliance rate and diagnostic yield. Radiology 1991;178:155-8.
    OpenUrlPubMed
  16. ↵
    Cardenosa G, Eklund GW. Rate of compliance with recommendations for additional mammographic views and biopsies. Radiology 1991;181:359-61.
    OpenUrlPubMed
  17. ↵
    Mandelblatt J, Traxler M, Larkin P, Kanetsky P, Kao R. Targeting breast and cervical cancer screening to elderly poor black women: who will participate? The Harlem Study Team. Prev Med 1993;22:20-33.
    OpenUrlCrossRefPubMed
  18. ↵
    Sienko DG, Hahn RA, Mills EM, et al. Mammography use and outcomes in a community The Greater Lansing Area Mammography Study. Cancer 1993;71:1801-9.
    OpenUrlCrossRefPubMed
  19. ↵
    Brown ML, Houn F, Sickles EA, Kessler LG. Screening mammography in community practice: Positive predictive value of abnormal findings and yield of follow-up diagnostic procedures. AJR Am J Roentgenol 1995;165:1373-7.
    OpenUrlPubMed
  20. ↵
    McCarthy BD, Yood MU, Boohaker EA, Ward RE, Rebner M, Johnson CC. Inadequate follow-up of abnormal mammograms. Am J Prev Med 1996;12:282-8.
    OpenUrlPubMed
  21. ↵
    Rojas M, Mandelblatt J, Cagney K, Kerner J, Freeman H. Barriers to follow-up of abnormal screening mammograms among low-income minority women Cancer Control Center of Harlem. Ethn Health 1996;1:221-8.
    OpenUrlPubMed
  22. ↵
    Webber PA, Fox P, Zhang X, Pond M. An examination of differential follow-up rates in breast cancer screening. J Commun Health 1996;21:123-32.
    OpenUrlCrossRefPubMed
  23. ↵
    Kann PE, Bradley C, Lane DS. Outcomes of recommendations for breast biopsies in women receiving mammograms from a county health van. Public Health Rep 1998;113:71-4.
    OpenUrlPubMed
  24. ↵
    Burack RC, Simon MS, Stano M, George J, Coombs J. Follow-up among women with an abnormal mammogram in an HMO: is it complete, timely, and efficient? Am J Manag Care 2000;6:1102-13.
    OpenUrlPubMed
  25. ↵
    Schootman M, Myers-Geadelmann J, Fuortes L. Factors associated with adequacy of diagnostic workup after abnormal breast cancer screening results. J Am Board Fam Pract 1999;13:94-100.
    OpenUrl
  26. ↵
    Haas JS, Cook EF, Puopolo AL, Burstin HR, Brennan TA. Differences in the quality of care for women with an abnormal mammogram or breast complaint. J Gen Intern Med 2000;15:321-8.
    OpenUrlCrossRefPubMed
  27. ↵
    Yabroff KR, Washington KS, Leader A, Neilson E, Mandelblatt J. Is the promise of cancer screening programs being compromised? Quality of follow-up care after abnormal screening results. Med Care Res Rev 2003;60:294-331.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Chang SW, Kerlikowske K, Napoles-Springer A, Posner SF, Sickles EA, Perez-Stable EJ. Racial differences in timeliness of follow-up after abnormal screening mammography. Cancer 1996;78:1395-402.
    OpenUrlCrossRefPubMed
  29. ↵
    Nelson K, Geiger AM, Mangione CM. Effect of health beliefs on delays in care for abnormal cervical cytology in a multi-ethnic population. J Gen Intern Med 2002;17:709-16.
    OpenUrlCrossRefPubMed
  30. ↵
    Lannin DR, Mathews HF, Mitchell J, Swanson MS, Swanson FH, Edwards MS. Influence of socioeconomic and cultural factors on racial differences in late-stage presentation of breast cancer. JAMA 1998;279:1801-7.
    OpenUrlCrossRefPubMed
  31. ↵
    Andersen R. A behavioral model of families use of health services. Chicago, IL; Center for Health Administration Studies, University of Chicago, t.p. 1974, 1968.
  32. ↵
    Andersen RM, Aday LA. Access to medical care in the US: realized and potential. Med Care 1978;16:533-46.
    OpenUrlCrossRefPubMed
  33. ↵
    Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav 1995;36:1-10.
    OpenUrlCrossRefPubMed
  34. ↵
    Becker MH, Maiman LA. Sociobehavioral determinants of compliance with health and medical care recommendations. Med Care 1975;13:10-24.
    OpenUrlCrossRefPubMed
  35. ↵
    Rakowski W, Breen N, Meissner H, et al. Prevalence and correlates of repeat mammography among women aged 55–79 in the year 2000 National Health Interview Survey. Prev Med. Submitted for publication 2003.
  36. ↵
    Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003;95:526-32.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Shah BV, Barnwell BG, Bieler GS. SUDAAN user's manual, release 7.5. 2003.
  39. ↵
    Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet 1999;353:1119-26.
    OpenUrlCrossRefPubMed
  40. ↵
    Ballard-Barbash R, Taplin SH, Yankaskas BC, et al. Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database. AJR Am J Roentgenol 1997;169:1001-8.
    OpenUrlCrossRefPubMed
  41. ↵
    Yankaskas BC, Jones MB, Aldrich TE. The Carolina Mamography Registry: a population-based mamography and cancer surveillance project. J Registry Manag 1996;23:175-8.
    OpenUrl
  42. ↵
    Carney PA, Poplack SP, Wells WA, Littenberg B. The New Hampshire Mammography Network: the development and design of a population-based registry. AJR Am J Roentgenol 1996;167:367-72.
    OpenUrlPubMed
  43. ↵
    Zapka JG, Taplin SH, Solberg LI, Manos MM. A framework for improving the quality of cancer care: the case of breast and cervical cancer screening. Cancer Epidemiol Biomark Prev 2003;12:4-13.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Boohaker EA, Ward RE, Uman JE, McCarthy BD. Patient notification and follow-up of abnormal test results: a physician survey. Arch Intern Med 1996;156:327-31.
    OpenUrlCrossRefPubMed
  45. ↵
    Myers RE, Balshem AM, Wolf TA, Ross EA, Millner L. Screening for colorectal neoplasia: physicians' adherence to complete diagnostic evaluation. Am J Public Health 1993;83:1620-2.
    OpenUrlPubMed
  46. ↵
    Myers RE, Turner B, Weinberg D, et al. Complete diagnostic evaluation in colorectal cancer screening: research design and baseline findings. Prev Med 2001;33:249-60.
    OpenUrlCrossRefPubMed
  47. ↵
    Myers RE, Fishbein G, Hyslop T, et al. Measuring complete diagnostic evaluation in colorectal cancer screening. Cancer Detect Prev 2001;25:174-82.
    OpenUrlPubMed
  48. ↵
    Turner B, Myers RE, Hyslop T, et al. Physician and patient factors associated with ordering a colon evaluation after a positive fecal occult blood test. J Gen Intern Med 2003;18:357-63.
    OpenUrlCrossRefPubMed
  49. ↵
    Yabroff KR, Klabunde CN, Myers R, Brown M. Physician recommendations for follow-up of positive fecal occult blood test. Med Care Res Rev. In press 2003.
  50. ↵
    Clarke EA, Anderson TW. Does screening by “Pap” smears help prevent cervical cancer? A case-control study. Lancet 1979;2:1-4.
    OpenUrlPubMed
  51. ↵
    La Vecchia C, Franceschi S, Decarli A. Papanicolaou smears and risk of cervical neoplasia. Lancet 1984;2:1335.
    OpenUrl
  52. ↵
    Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1365-71.
    OpenUrlCrossRefPubMed
  53. ↵
    Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst 1993;85:1311-8.
    OpenUrlAbstract/FREE Full Text
  54. ↵
    Fox P, Amsberger P, Zhang X. An examination of differential follow-up rates in cervical cancer screening. J Commun Health 1997;22:199-209.
    OpenUrlCrossRefPubMed
  55. ↵
    Benard VB, Lee NC, Piper M, Richardson L. Race-specific results of Papanicolaou testing and the rate of cervical neoplasia in the National Breast and Cervical Cancer Early Detection Program, 1991–1998 (United States). Cancer Causes Control 2001;12:61-8.
    OpenUrlCrossRefPubMed
  56. ↵
    McGarrity TJ, Long PA, Peiffer LP. Results of a repeat television-advertised mass screening program for colorectal cancer using fecal occult blood tests. Am J Gastroenterol 1990;85:266-70.
    OpenUrlPubMed
  57. ↵
    Schwarz PJ, Fasal E, Simmons ME. 12-County program: Screening of 34,318 women for cervical cancer in California, 1975–78. Public Health Rep 1981;96:547-54.
    OpenUrlPubMed
  58. ↵
    Lane DS. Compliance with referrals from a cancer-screening project. J Fam Pract 1983;17:811-7.
    OpenUrlPubMed
  59. ↵
    Michielutte R, Diseker RA, Young LD, May WJ. Noncompliance in screening follow-up among family planning clinic patients with cervical dysplasia. Prev Med 1985;14:248-58.
    OpenUrlCrossRefPubMed
  60. ↵
    Estrin HM. Classification, management, and tracking of abnormal Papanicolaou smears. J Am Coll Health 1989;37:283-7.
    OpenUrlPubMed
  61. ↵
    Carey P, Gjerdingen DK. Follow-up of abnormal Papanicolaou smears among women of different races. J Fam Pract 1993;37:583-7.
    OpenUrlPubMed
  62. ↵
    Funke BL, Nicholson ME. Factors affecting patient compliance among women abnormal pap smears. Patient Educ Couns 1993;20:5-15.
    OpenUrlCrossRefPubMed
  63. ↵
    Gilbert TJ, Sugarman JR, Cobb N. Abnormal Papanicolaou smears and colposcopic follow-up among American Indian and Alaska Native women in the Pacific northwest. J Am Board Fam Pract 1995;8:183-8.
  64. ↵
    Kaplan CP, Bastani R, Marcus A, Breslow L, Nasseri K, Chen L. Low-income women with cervical abnormalities: individual and system factors affecting follow-up. J Womens Health 1995;4:179-88.
    OpenUrl
  65. ↵
    Crane LA. Social support and adherence behavior among women with abnormal Pap smears. J Cancer Educ 1996;11:164-73.
    OpenUrlPubMed
  66. ↵
    Howell LP, Davis RL. Follow-up of Papanicolaou smears diagnosed as atypical squamous cells of undetermined significance. Diagn Cytopathol 1996;14:20-4.
    OpenUrlCrossRefPubMed
  67. ↵
    McKee MD, Lurio J, Marantz P, Burton W, Mulvihill M. Barriers to follow-up of abnormal Papanicolaou smears in an urban community health center. Arch Fam Med 1999;8:129-34.
    OpenUrlCrossRefPubMed
  68. ↵
    McKee MD, Schechter C, Burton W, Mulvihill M. Predictors of follow-up of atypical and ASCUS papanicolaou tests in a high-risk population. J Fam Pract 2001;50:609.
    OpenUrlPubMed
  69. ↵
    Melnikow J, Chan BK, Stewart GK. Do follow-up recommendations for abnormal Papanicolaou smears influence patient adherence? Arch Fam Med 1999;8:510-4.
    OpenUrlCrossRefPubMed
  70. ↵
    Cejtin HE, Komaroff E, Massad LS, et al. Adherence to colposcopy among women with HIV infection. J Acquir Immune Defic Syndr 1999;22:247-52.
  71. ↵
    Cummings KM, Michalek A, Mettlin C, Mittelman A. Screening for colorectal cancer using the Hemoccult II stool guaiac slide test. Cancer 1984;53:2201-5.
    OpenUrlCrossRefPubMed
  72. ↵
    Tressler C, McClatchey M, Calonge N, et al. An analysis of factors associated with non-compliance with follow-up recommendations after a positive fecal occult blood test. Prog Clin Biol Res 1989;293:307-22.
    OpenUrlPubMed
  73. ↵
    Morris JB, Stellato TA, Guy BB, Gordon NH, Berger NA. A critical analysis of the largest reported mass fecal occult blood screening program in the United States. Am J Surg 1991;161:101-5.
    OpenUrlCrossRefPubMed
  74. ↵
    Klos SE, Drinka P, Goodwin JS. The utilization of fecal occult blood testing in the institutionalized elderly. J Am Geriatr Soc 1991;39:1169-73.
    OpenUrlPubMed
  75. ↵
    Levin B, Hess K, Johnson C. Screening for colorectal cancer: a comparison of 3 fecal occult blood tests. Arch Intern Med 1997;157:970-6.
    OpenUrlCrossRefPubMed
  76. ↵
    Lurie JD, Welch HG. Diagnostic testing following fecal occult blood screening in the elderly. J Natl Cancer Inst 1999;91:1641-6.
    OpenUrlAbstract/FREE Full Text
  77. ↵
    Jones BA, Novis DA. Follow-up of abnormal gynecologic cytology: a College of American Pathologists Q-Probes study of 16132 cases from 306 laboratories. Arch Pathol Lab Med 2000;124:665-71.
    OpenUrlPubMed
  78. ↵
    Hogness CG, Engelstad LP, Linck LM, Schorr KA. Cervical cancer screening in an urban emergency department. Ann Emerg Med 1992;21:933-9.
    OpenUrlCrossRefPubMed
  79. ↵
    Lavin C, Goodman E, Perlman S, Kelly LS, Emans SJ. Follow-up of abnormal Papanicolaou smears in a hospital-based adolescent clinic. J Pediatr Adolesc Gynecol 1997;10:141-5.
    OpenUrlPubMed
  80. ↵
    Khubchandani IT, Karamchandani MC, Kleckner FS, et al. Mass screening for colorectal cancer. Dis Colon Rectum 1989;32:754-8.
    OpenUrlPubMed
  81. ↵
    McGarrity TJ, Long PA, Peiffer LP, Converse JO, Kreig AF. Results of a television-advertised public screening program for colorectal cancer. Arch Intern Med 1989;149:140-4.
    OpenUrlCrossRefPubMed
  82. ↵
    Lerman C, Hanjani P, Caputo C, et al. Telephone counseling improves adherence to colposcopy among lower-income minority women. J Clin Oncol 1992;10:330-3.
    OpenUrlAbstract
  83. ↵
    Marcus AC, Crane LA, Kaplan CP, et al. Improving adherence to screening follow-up among women with abnormal Pap smears: results from a large clinic-based trial of three intervention strategies. Med Care 1992;30:216-29.
    OpenUrlCrossRefPubMed
  84. ↵
    Paskett ED, Carter WB, Chu J, White E. Compliance behavior in women with abnormal Pap smears: developing and testing a decision model. Med Care 1990;28:643-56.
    OpenUrlCrossRefPubMed
  85. ↵
    Yabroff KR, Mandelblatt JS, Kerner JF. Effectiveness of interventions to improve follow-up after abnormal cervical cancer screening. Prev Med 2000;31:429-439.
    OpenUrlCrossRefPubMed
  86. ↵
    Sudano JJ, Baker DW. Intermittent lack of health insurance coverage and use of preventive services. Am J Public Health 2003;93:130-7.
    OpenUrlPubMed
  87. ↵
    Newell SA, Girgis A, Sanson-Fisher RW, Savolainen NJ, Hons BA. The accuracy of self-reported health behaviors and risk factors relating to cancer and cardiovascular disease in the general population: a critical review. Am J Prev Med 1999;17:211-29.
    OpenUrlCrossRefPubMed
  88. ↵
    Gordon NP, Hiatt RA, Lampert DI. Concordance of self-reported data and medical record audit for six cancer screening procedures. J Natl Cancer Inst 1993;85:566-70.
    OpenUrlAbstract/FREE Full Text
  89. ↵
    Hiatt RA, Perez-Stable EJ, Quesenberry CP Jr, Sabogal F, Otero-Sabogal R, McPhee SJ. Agreement between self-reported early cancer detection practices and medical audits among Hispanic and non Hispanic white health plan members in northern California. Prev Med 1995;24:278-85.
    OpenUrlCrossRefPubMed
  90. ↵
    Paskett ED, Tatum CM, Mack DW, Hoen H, Case LD, Velez R. Validation of self-reported breast and cervical cancer screening tests among low-income minority women. Cancer Epidemiol Biomark Prev (US) 1996;5:721-6.
    OpenUrl
  91. ↵
    Zapka JG, Bigelow C, Hurley T, et al. Mammography use among sociodemographically diverse women: the accuracy of self-report. Am J Public Health 1996;86:1016-21.
    OpenUrlPubMed
  92. ↵
    California Health Interview Survey. http://www.chis.ucla.edu/index.html, 2003.
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 13 (5)
May 2004
Volume 13, Issue 5
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
What Factors Are Associated with Diagnostic Follow-Up after Abnormal Mammograms? Findings from a U.S. National Survey
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
What Factors Are Associated with Diagnostic Follow-Up after Abnormal Mammograms? Findings from a U.S. National Survey
K. Robin Yabroff, Nancy Breen, Sally W. Vernon, Helen I. Meissner, Andrew N. Freedman and Rachel Ballard-Barbash
Cancer Epidemiol Biomarkers Prev May 1 2004 (13) (5) 723-732;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
What Factors Are Associated with Diagnostic Follow-Up after Abnormal Mammograms? Findings from a U.S. National Survey
K. Robin Yabroff, Nancy Breen, Sally W. Vernon, Helen I. Meissner, Andrew N. Freedman and Rachel Ballard-Barbash
Cancer Epidemiol Biomarkers Prev May 1 2004 (13) (5) 723-732;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Early-Life Risk Factors for Breast Cancer
  • Sugary Drink Consumption and Colorectal Cancer Risk
  • HPV Testing in Self-samples and Urine
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement